S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)

Cara Therapeutics (CARA) Stock Price, News & Analysis

$0.88
+0.01 (+1.27%)
(As of 02:24 PM ET)
Today's Range
$0.85
$0.96
50-Day Range
$0.52
$1.05
52-Week Range
$0.50
$5.20
Volume
417,862 shs
Average Volume
732,658 shs
Market Capitalization
$48.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.75

Cara Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
948.4% Upside
$9.75 Price Target
Short Interest
Bearish
5.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.39
Upright™ Environmental Score
News Sentiment
1.89mentions of Cara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$28,621 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.25) to ($1.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.53 out of 5 stars

Medical Sector

202nd out of 939 stocks

Pharmaceutical Preparations Industry

82nd out of 433 stocks

CARA stock logo

About Cara Therapeutics Stock (NASDAQ:CARA)

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

CARA Stock Price History

CARA Stock News Headlines

Demystifying Cara Therapeutics: Insights From 4 Analyst Reviews
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
CARA Apr 2024 5.000 call
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Q4 2023 Cara Therapeutics Inc Earnings Call
Here's what Wall Street expects from Cara Therapeutics's earnings
See More Headlines
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/04/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CARA
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.75
High Stock Price Target
$25.00
Low Stock Price Target
$2.50
Potential Upside/Downside
+948.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-118,510,000.00
Net Margins
-565.21%
Pretax Margin
-565.21%

Debt

Sales & Book Value

Annual Sales
$20.97 million
Book Value
$1.05 per share

Miscellaneous

Free Float
52,360,000
Market Cap
$50.83 million
Optionable
Optionable
Beta
0.70
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

CARA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CARA shares.
View CARA analyst ratings
or view top-rated stocks.

What is Cara Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 12 month price targets for Cara Therapeutics' shares. Their CARA share price targets range from $2.50 to $25.00. On average, they expect the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 948.4% from the stock's current price.
View analysts price targets for CARA
or view top-rated stocks among Wall Street analysts.

How have CARA shares performed in 2024?

Cara Therapeutics' stock was trading at $0.7430 on January 1st, 2024. Since then, CARA shares have increased by 25.2% and is now trading at $0.93.
View the best growth stocks for 2024 here
.

When is Cara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CARA earnings forecast
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.02. The biopharmaceutical company earned $3 million during the quarter, compared to the consensus estimate of $2.34 million. Cara Therapeutics had a negative net margin of 565.21% and a negative trailing twelve-month return on equity of 122.10%. During the same period in the prior year, the firm posted ($0.56) earnings per share.

What ETF holds Cara Therapeutics' stock?

Amplify Seymour Cannabis ETF holds 161,542 shares of CARA stock, representing 1.93% of its portfolio.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.83%), Vanguard Group Inc. (4.83%), Federated Hermes Inc. (1.53%), Verition Fund Management LLC (1.01%), Northern Trust Corp (0.72%) and Stifel Financial Corp (0.57%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Ryan D Maynard, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends
.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CARA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners